Fusion Antibodies (LON:FAB) Announces Quarterly Earnings Results

Fusion Antibodies (LON:FAB) announced its quarterly earnings results on Monday. The company reported GBX (1.20) earnings per share for the quarter, Digital Look Earnings reports. Fusion Antibodies had a negative return on equity of 210.32% and a negative net margin of 91.92%.

Fusion Antibodies Trading Up 14.1%

Fusion Antibodies stock traded up GBX 1.30 during mid-day trading on Tuesday, hitting GBX 10.55. 1,644,497 shares of the company’s stock were exchanged, compared to its average volume of 424,310. The company’s 50 day simple moving average is GBX 10.84 and its 200-day simple moving average is GBX 12.16. The company has a quick ratio of 2.36, a current ratio of 1.80 and a debt-to-equity ratio of 92.42. The firm has a market capitalization of £13.20 million, a P/E ratio of -7.03 and a beta of 1.24. Fusion Antibodies has a fifty-two week low of GBX 9 and a fifty-two week high of GBX 21.

Fusion Antibodies Company Profile

Fusion is a Belfast based contract research organisation (“CRO”) providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.

The Company’s ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion’s proprietary CDRx TM platform and the production of antibody generating stable cell lines to provide material for use in clinical trials.